医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

KBRA Releases Comment on the Coronavirus and its Effect on the Commercial Aviation Industry

2020年02月01日 AM07:02
このエントリーをはてなブックマークに追加


 

NEW YORK

Kroll Bond Rating Agency (KBRA) releases a comment on the Wuhan coronavirus outbreak in China and beyond, and its potential impact on the airline industry.

The commercial airline industry is cyclical and continually faces many challenges including volatile oil prices, weak economic conditions, labor issues, and competition. However, the industry is also vulnerable to event risks such as terrorism, pandemics, political instability, and natural disasters—all of which could curtail passenger travel in a very short time following a major event.

KBRA notes that while external shocks are often followed by a decline in passenger travel, such drops have been temporary and passenger growth has rebounded quickly. That said, the impact on revenues for affected airlines, while temporary, has in most cases led to consequences for these airlines’ credit profiles and access to capital markets—even if in the short term. Further, airlines globally are at risk of a change in consumer travel behavior as a result of the coronavirus.

To access the comment, click here.

CONNECT WITH KBRA

Twitter
LinkedIn
YouTube

About KBRA and KBRA Europe

KBRA is a full-service credit rating agency registered with the U.S. Securities and Exchange Commission as an NRSRO. In addition, KBRA is designated as a designated rating organization by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized by the National Association of Insurance Commissioners as a Credit Rating Provider and is a certified Credit Rating Agency (CRA) by the European Securities and Markets Authority (ESMA). Kroll Bond Rating Agency Europe Limited is registered with ESMA as a CRA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005592/en/

CONTACT

Analytical:

Thomas Moore, Senior Analyst

(646) 731-3375

tmoore@kbra.com

Marjan Riggi, Senior Managing Director

(646) 731-2354

mriggi@kbra.com

Business Development:

Nish Kumar, Senior Director

(646) 731-3372

nkumar@kbra.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表